Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nuvectis Pharma Inc (NVCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NVCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.17
1 Year Target Price $18.17
| 2 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.32% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 163.69M USD | Price to earnings Ratio - | 1Y Target Price 18.17 |
Price to earnings Ratio - | 1Y Target Price 18.17 | ||
Volume (30-day avg) 6 | Beta -0.27 | 52 Weeks Range 4.44 - 11.80 | Updated Date 08/15/2025 |
52 Weeks Range 4.44 - 11.80 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.25 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -63.38% | Return on Equity (TTM) -150.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 136894532 | Price to Sales(TTM) - |
Enterprise Value 136894532 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.38 | Shares Outstanding 25456800 | Shares Floating 14536624 |
Shares Outstanding 25456800 | Shares Floating 14536624 | ||
Percent Insiders 43.55 | Percent Institutions 13.83 |
Upturn AI SWOT
Nuvectis Pharma Inc
Company Overview
History and Background
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious unmet medical needs in oncology. Founded with a vision to transform cancer treatment, it leverages advanced scientific insights to develop targeted therapies.
Core Business Areas
- Drug Development: Nuvectis Pharma focuses on developing innovative therapies for cancer with high unmet needs. Their strategy includes precision medicine approaches targeting specific genetic mutations or pathways.
Leadership and Structure
Nuvectis Pharma is led by a management team with experience in drug development. Specific leadership details and organizational structure would be detailed in company reports.
Top Products and Market Share
Key Offerings
- NXP800: A Heat Shock Factor 1 (HSF1) pathway inhibitor in Phase 1 clinical trials for advanced cancers, including platinum-resistant ovarian cancer (PROC) and clear cell ovarian cancer (CCOC). Market share data is not available as it is still in clinical trials. Competitors developing HSF1 inhibitors or treatments for ovarian cancer include major pharmaceutical companies with broad oncology portfolios.
Market Dynamics
Industry Overview
The oncology market is characterized by high growth driven by aging populations and advancements in personalized medicine and targeted therapies. It's a competitive space with many established and emerging companies.
Positioning
Nuvectis Pharma is positioned as a precision medicine company developing targeted therapies in oncology. Its competitive advantage lies in its approach of developing drugs targeting the HSF1 pathway, a novel approach to cancer treatment.
Total Addressable Market (TAM)
The TAM for oncology treatments is substantial, estimated to be hundreds of billions of dollars annually. Nuvectis Pharma is focusing on specific cancer subtypes (e.g., platinum-resistant ovarian cancer) to address unmet needs within the broader oncology market.
Upturn SWOT Analysis
Strengths
- Novel drug development approach (HSF1 inhibitor)
- Focus on unmet medical needs in oncology
- Precision medicine strategy
Weaknesses
- Early stage clinical development (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on single drug candidate (NXP800)
Opportunities
- Positive clinical trial results for NXP800
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
Threats
- Clinical trial failures
- Competition from established oncology therapies
- Regulatory hurdles and approval delays
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
- AZN
- GILD
Competitive Landscape
Nuvectis Pharma faces competition from established pharmaceutical companies with broad oncology portfolios. Its advantage is its novel approach, but it is significantly smaller and less established than its competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited given its development stage. Growth potential is tied to future clinical trial results and potential commercialization.
Future Projections: Future projections depend on the success of NXP800 and any pipeline expansion. Analyst estimates would provide insights into potential revenue and profitability timelines.
Recent Initiatives: Recent initiatives include advancing NXP800 through Phase 1 clinical trials.
Summary
Nuvectis Pharma is a development-stage biopharmaceutical company with a focus on precision oncology. Their innovative approach of targeting the HSF1 pathway provides an opportunity, but it faces high clinical development risk and competition. Financial stability and successful clinical trials are crucial for the company's future growth. The company needs to be aware of clinical trial failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. The data is subject to change. Market share estimates are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvectis Pharma Inc
Exchange NASDAQ | Headquaters Fort Lee, NJ, United States | ||
IPO Launch date 2022-02-04 | Co-Founder, Chairman, CEO & President Mr. Ron Bentsur M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.nuvectis.com |
Full time employees 13 | Website https://www.nuvectis.com | ||
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.